Natural killer T cell activation increases iNOS
Animals
Lectins, C-Type
/ immunology
Lymphocyte Activation
Macrophages
/ enzymology
Male
Mannose Receptor
Mannose-Binding Lectins
/ immunology
Melanoma, Experimental
/ enzymology
Mice
Mice, Inbred C57BL
Natural Killer T-Cells
/ enzymology
Nitric Oxide Synthase Type II
/ immunology
Receptors, Cell Surface
/ immunology
Tumor Microenvironment
/ immunology
CD1d
Macrophage polarization
Melanoma
Natural killer T cells
Th1
Tumor microenvironment
Journal
Journal for immunotherapy of cancer
ISSN: 2051-1426
Titre abrégé: J Immunother Cancer
Pays: England
ID NLM: 101620585
Informations de publication
Date de publication:
06 08 2019
06 08 2019
Historique:
received:
07
03
2019
accepted:
30
07
2019
entrez:
8
8
2019
pubmed:
8
8
2019
medline:
29
8
2020
Statut:
epublish
Résumé
NKT cells play an important role in anti-tumor immunity. Alpha-galactosylceramide (α-GalCer), a synthetic glycolipid is presented to natural killer T (NKT) cells by most antigen-presenting cells through CD1d molecules leading to activation of NKT cells. However, the precise mechanisms of how α-GalCer-activated NKT regulate the polarization of the macrophages and effector T cells in the solid tumor are not studied adequately. We induced solid tumor in C57BL/6 mice by subcutaneous injection of B16F10 cell line (1 X 10 Our results showed that intratumoral NKT cells have a lower frequency of CD69, CD25, CD122, and IFN-γR expression; produced less inflammatory cytokines such as IFN-γ, TNF-α, and GM-CSF; higher frequency CD62L We showed that activation of NKT cell with α-GalCer modulates the frequency of M1-macrophages and effector Th1 cells in the secondary lymphoid tissues and tumor microenvironment and inhibit tumor growth. The finding suggests that activation of NKT cells with α-GalCer may provide an effective anti-cancer outcome.
Sections du résumé
BACKGROUND
NKT cells play an important role in anti-tumor immunity. Alpha-galactosylceramide (α-GalCer), a synthetic glycolipid is presented to natural killer T (NKT) cells by most antigen-presenting cells through CD1d molecules leading to activation of NKT cells. However, the precise mechanisms of how α-GalCer-activated NKT regulate the polarization of the macrophages and effector T cells in the solid tumor are not studied adequately.
METHODS
We induced solid tumor in C57BL/6 mice by subcutaneous injection of B16F10 cell line (1 X 10
RESULTS
Our results showed that intratumoral NKT cells have a lower frequency of CD69, CD25, CD122, and IFN-γR expression; produced less inflammatory cytokines such as IFN-γ, TNF-α, and GM-CSF; higher frequency CD62L
CONCLUSIONS
We showed that activation of NKT cell with α-GalCer modulates the frequency of M1-macrophages and effector Th1 cells in the secondary lymphoid tissues and tumor microenvironment and inhibit tumor growth. The finding suggests that activation of NKT cells with α-GalCer may provide an effective anti-cancer outcome.
Identifiants
pubmed: 31387637
doi: 10.1186/s40425-019-0697-7
pii: 10.1186/s40425-019-0697-7
pmc: PMC6685184
doi:
Substances chimiques
Lectins, C-Type
0
Mannose Receptor
0
Mannose-Binding Lectins
0
Receptors, Cell Surface
0
Nitric Oxide Synthase Type II
EC 1.14.13.39
Nos2 protein, mouse
EC 1.14.13.39
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
208Références
J Immunol. 1999 Sep 1;163(5):2387-91
pubmed: 10452972
J Immunol. 1999 Dec 1;163(11):5871-6
pubmed: 10570271
Blood. 2000 Apr 1;95(7):2440-2
pubmed: 10733519
Int Immunol. 2001 Apr;13(4):459-63
pubmed: 11282985
J Immunol. 2001 Oct 1;167(7):4046-50
pubmed: 11564825
Blood. 2002 Feb 15;99(4):1259-66
pubmed: 11830474
Int J Cancer. 2002 Nov 10;102(2):159-65
pubmed: 12385012
Clin Cancer Res. 2002 Dec;8(12):3702-9
pubmed: 12473579
J Exp Med. 2003 Jun 16;197(12):1667-76
pubmed: 12796469
Proc Natl Acad Sci U S A. 2003 Aug 5;100(16):9464-9
pubmed: 12867593
J Immunol. 2003 Dec 1;171(11):5913-20
pubmed: 14634102
Blood. 2004 Dec 15;104(13):4150-6
pubmed: 15328159
Eur J Immunol. 2004 Oct;34(10):2664-71
pubmed: 15368282
Br J Cancer. 2004 Nov 29;91(11):1880-6
pubmed: 15520823
J Clin Invest. 2004 Nov;114(10):1379-88
pubmed: 15545985
Int J Cancer. 2005 Aug 10;116(1):87-93
pubmed: 15756674
J Exp Med. 2005 Jun 20;201(12):1973-85
pubmed: 15967825
J Clin Invest. 2005 Sep;115(9):2572-83
pubmed: 16138194
Clin Cancer Res. 2005 Oct 15;11(20):7322-7
pubmed: 16243803
J Exp Med. 2005 Nov 7;202(9):1279-88
pubmed: 16275765
J Immunol. 2006 Jul 15;177(2):769-75
pubmed: 16818729
PLoS One. 2006 Dec 20;1:e50
pubmed: 17183680
J Immunol. 2007 Mar 1;178(5):2827-34
pubmed: 17312126
J Clin Oncol. 2007 Mar 1;25(7):862-8
pubmed: 17327607
J Exp Med. 2007 May 14;204(5):995-1001
pubmed: 17470641
J Immunol. 2007 Oct 15;179(8):5126-36
pubmed: 17911598
J Exp Med. 2007 Oct 29;204(11):2641-53
pubmed: 17923500
Immunol Lett. 2008 Jun 15;118(1):36-43
pubmed: 18405982
J Immunol. 2008 Aug 15;181(4):2446-54
pubmed: 18684935
Proc Natl Acad Sci U S A. 2008 Aug 12;105(32):11287-92
pubmed: 18685112
J Immunol. 2009 Mar 1;182(5):2816-26
pubmed: 19234176
J Immunol. 2009 Apr 15;182(8):5140-51
pubmed: 19342695
J Clin Invest. 2009 Jun;119(6):1524-36
pubmed: 19411762
Proc Natl Acad Sci U S A. 2009 Oct 20;106(42):17847-51
pubmed: 19815501
Proc Natl Acad Sci U S A. 2010 Jun 15;107(24):10984-9
pubmed: 20534460
Proc Natl Acad Sci U S A. 2010 Dec 14;107(50):21659-64
pubmed: 21118979
J Immunol. 2011 Dec 15;187(12):6335-45
pubmed: 22084435
PLoS Biol. 2012 Feb;10(2):e1001255
pubmed: 22346732
J Clin Invest. 2012 Jun;122(6):2221-33
pubmed: 22565311
Clin Dev Immunol. 2012;2012:720803
pubmed: 23118781
Oncoimmunology. 2012 Nov 1;1(8):1323-1343
pubmed: 23243596
Front Immunol. 2014 Oct 17;5:514
pubmed: 25368618
Immunity. 2015 Sep 15;43(3):566-78
pubmed: 26362265
J Clin Invest. 2016 Jun 1;126(6):2341-55
pubmed: 27183388
J Immunol. 2017 Feb 1;198(3):1015-1021
pubmed: 28115591
Oncoimmunology. 2016 Sep 20;5(12):e1235106
pubmed: 28151533
Immunology. 2017 Sep;152(1):36-51
pubmed: 28419443
Oncoimmunology. 2017 Aug 18;6(9):e1339855
pubmed: 28932640
Front Immunol. 2017 Sep 13;8:1124
pubmed: 28955340
Front Immunol. 2017 Sep 25;8:1206
pubmed: 28993781
Front Immunol. 2017 Sep 22;8:1178
pubmed: 29018445
Cancer Immunol Res. 2017 Dec;5(12):1086-1097
pubmed: 29054890
Cancer Immunol Immunother. 2018 Feb;67(2):285-298
pubmed: 29094183
Front Immunol. 2017 Nov 01;8:1417
pubmed: 29163493
Nat Commun. 2018 Feb 15;9(1):684
pubmed: 29449556
Cell Rep. 2018 Mar 13;22(11):3006-3020
pubmed: 29539427
Front Immunol. 2018 Mar 02;9:384
pubmed: 29559971
Cell Chem Biol. 2018 May 17;25(5):571-584.e8
pubmed: 29576533
Glycobiology. 2018 Jul 1;28(7):512-521
pubmed: 29688330
Science. 1995 May 12;268(5212):863-5
pubmed: 7538697
Proc Natl Acad Sci U S A. 1998 May 12;95(10):5690-3
pubmed: 9576945